BioCentury
ARTICLE | Clinical News

Controlled release nitazoxanide: Phase I data

February 23, 2009 8:00 AM UTC

In the double-blind, crossover Phase I OPTIMA HCN-1 trial in 12 healthy volunteers, twice-daily 675 and 1,350 mg controlled release nitazoxanide produced trough plasma concentrations of tizoxanide, th...